Class Of Warrant Or Right, Exercise Period

No definition available.

Name:	asrt_ClassOfWarrantOrRightExercisePeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Commercialization Agreement, Net Annual Sales Threshold

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementNetAnnualSalesThreshold
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commercialization Agreement, Reimbursement Of Royalties, Period

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementReimbursementOfRoyaltiesPeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Commercialization Agreement, Termination, Net Sales Threshold

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementTerminationNetSalesThreshold
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commercialization Agreement, Warrant Value

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementWarrantValue
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the termination fee the counterparty can pay to cancel the agreement per terms of the agreement.

+ References

No definition available.

+ Details

Name:	asrt_CounterpartyTerminationFee
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the equal quarterly installments of annual minimum royalty payable.

+ References

No definition available.

+ Details

Name:	asrt_EqualQuarterlyInstallmentsOfAnnualMinimumRoyaltyPayable
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the milestone payment received by the entity during the period.

+ References

No definition available.

+ Details

Name:	asrt_MilestonePaymentReceived
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of performance obligations the Company has under the agreement.

+ References

No definition available.

+ Details

Name:	asrt_NumberOfPerformanceObligations
Namespace Prefix:	asrt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the percentage of royalty on annual net sales.

+ References

No definition available.

+ Details

Name:	asrt_PercentageOfRoyaltyOnAnnualNetSales
Namespace Prefix:	asrt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The proceeds from the transfer of inventory per the agreement.

+ References

No definition available.

+ Details

Name:	asrt_ProceedsFromTransferOfInventory
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue From Contract With Customer, Excluding Assessed Tax, Gross-To-Net Adjustment

+ References

No definition available.

+ Details

Name:	asrt_RevenueFromContractWithCustomerExcludingAssessedTaxGrossToNetAdjustment
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The upfront payment received on closing of the transaction.

+ References

No definition available.

+ Details

Name:	asrt_RevenueRecognitionUpfrontPayment
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount recorded during the period related to the reduction of sales reserves.

+ References

No definition available.

+ Details

Name:	asrt_ReversalOfSalesReserves
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty Arrangement, Annual Payments, Term

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementAnnualPaymentsTerm
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Arrangement, Quarterly Payments, Term

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementQuarterlyPaymentsTerm
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Arrangement, Termination Period

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementTerminationPeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The annual royalty obligation per the agreement.

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyObligation
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total minimum royalties that will be earned per the agreement.

+ References

No definition available.

+ Details

Name:	asrt_TotalMinimumAnnualRoyalties
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_IncreaseDecreaseInContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfWarrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromRoyaltiesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=asrt_JanssenNucyntaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=asrt_CommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=asrt_RoyaltiesAndMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=asrt_RevenueFromTransferOfInventoryFromCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=asrt_IronwoodPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=asrt_MilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=asrt_CollegiumPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=asrt_PDLBioPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_FutureRoyaltyLiabilityArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=asrt_ThirdPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_AllNucyntaProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_PerformanceObligationTransferOfFinishedGoodsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_PerformanceObligationCommercializeAndFacilitationServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_AmendedCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement65RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement14RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement58RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement20RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement15RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement25RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement17.5RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreementAndAmendedCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=asrt_ThirdPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=asrt_CollegiumPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

REVENUE - Narrative (Details)					1 Months Ended			3 Months Ended								10 Months Ended	12 Months Ended				36 Months Ended	48 Months Ended
REVENUE - Narrative (Details)	Jan. 01, 2022 USD ($)	Jan. 01, 2019	Nov. 08, 2018 USD ($) $ / shares shares	Jan. 09, 2018 USD ($)	Nov. 30, 2018 USD ($)	Jan. 31, 2018 USD ($) performance_obligation	Oct. 31, 2013 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Nov. 08, 2018 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Aug. 02, 2018 USD ($)
Collaboration and License Agreements
Total revenues								$ 42,599,000	$ 77,493,000	$ 63,274,000	$ 128,404,000	$ 94,407,000	$ 95,413,000	$ 100,457,000	$ 90,447,000			$ 311,770,000	$ 380,724,000	$ 455,897,000
Contract asset								2,416,000				0						2,416,000	0
NUCYNTA products
Collaboration and License Agreements
Product revenue recognized											12,500,000
Total revenues																		18,944,000	239,539,000	281,261,000
Product sales, net
Collaboration and License Agreements
Total revenues								29,339,000	29,435,000	26,838,000	$ 44,354,000	94,159,000	$ 95,204,000	$ 100,232,000	$ 90,285,000			129,966,000	379,880,000	455,066,000
Commercialization agreement, net
Collaboration and License Agreements
Total revenues																		155,743,000	0	0
Royalties and milestones
Collaboration and License Agreements
Total revenues																		26,061,000	844,000	831,000
Revenue from transfer of inventory
Collaboration and License Agreements
Total revenues																		55,705,000	0	$ 0
Ironwood Pharmaceuticals, Inc.
Collaboration and License Agreements
Contract asset								0				0						0	0
Ironwood Pharmaceuticals, Inc. \| Milestone Payment
Collaboration and License Agreements
Total revenues									5,000,000	5,000,000									0
Milestone payment received									5,000,000
Collegium Pharmaceutical Inc
Collaboration and License Agreements
Contract asset								2,416,000				$ 0						2,416,000	$ 0
Contract liability						$ 10,000,000
Collegium warrants						$ 8,800,000
PDL BioPharma \| Royalties and milestones
Collaboration and License Agreements
Royalty and milestone payments received							$ 240,500,000
Future Royalty Liability Arrangement \| PDL BioPharma
Collaboration and License Agreements
Royalty and milestone payments received							$ 240,500,000
Total sales price																							$ 20,000,000
Future Royalty Liability Arrangement \| PDL BioPharma \| Royalties and milestones
Collaboration and License Agreements
Total revenues									20,000,000
Commercialization agreement, net \| Third Party \| Royalties and milestones
Collaboration and License Agreements
Increase in royalties obligation																		34,000,000
Commercialization agreement, net \| NUCYNTA products \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Number of performance obligations (performance obligation) \| performance_obligation						3
Transaction price						$ 553,200,000
Total minimum annual royalties						537,000,000
Upfront payment						10,000,000												10,000,000
Proceeds from transfer of inventory						6,200,000
Commercialization agreement, net \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Royalty arrangement, annual payments term	60 days
Performance Obligation Transfer Of Finished Goods \| Collegium Pharmaceutical Inc \| Revenue from transfer of inventory
Collaboration and License Agreements
Total revenues																		55,700,000
Performance Obligation Transfer Of Finished Goods \| NUCYNTA products \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Transaction price						55,700,000
Performance Obligation Commercialize And Facilitation Services \| Collegium Pharmaceutical Inc \| Royalties and milestones
Collaboration and License Agreements
Total revenues																$ 103,800,000
Performance Obligation Commercialize And Facilitation Services \| NUCYNTA products \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Transaction price						497,500,000
Amended Commercialization Agreement \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Transaction price					$ 157,000,000
Total minimum annual royalties					132,000,000
Upfront payment					10,000,000
Proceeds from transfer of inventory					6,200,000
Commercialization agreement, warrant to purchase shares (in shares) \| shares			1,041,667													1,041,667
Commercialization agreement, exercise price (in dollars per share) \| $ / shares			$ 19.20													$ 19.20
Commercialization agreement, warrant exercise period			4 years
Commercialization agreement, value of warrant			$ 8,800,000													$ 8,800,000
Commercialization agreement, warrant value in transaction price					$ 8,800,000
Royalty arrangement, termination notice period					60 days
Amended Commercialization Agreement \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, reimbursement of royalties term		4 years
Royalty arrangement, termination notice period	12 months																12 months
Commercialization Agreement, 65% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales																	65.00%				65.00%	65.00%
Commercialization agreement, net annual sales threshold																					$ 180,000,000
Commercialization Agreement, 14% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales																	14.00%				14.00%	14.00%
Commercialization Agreement, 58% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales	58.00%																58.00%				58.00%	58.00%
Commercialization agreement, net annual sales threshold	$ 233,000,000
Commercialization Agreement, 20% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales																	20.00%				20.00%	20.00%
Commercialization Agreement, 15% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales																	15.00%				15.00%	15.00%
Commercialization agreement, net annual sales threshold																					$ 258,000,000
Commercialization Agreement, 25% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales	25.00%
Commercialization Agreement, 17.5% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Percentage of royalty on annual net sales	17.50%
Commercialization agreement, net annual sales threshold	$ 258,000,000
Commercialization Agreement And Amended Commercialization Agreement \| Third Party \| Royalties and milestones
Collaboration and License Agreements
Gross-to-net revenue adjustment																		3,700,000
Commercialization Agreement And Amended Commercialization Agreement \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Proceeds from transfer of inventory																		6,200,000
Royalty payments received																		132,000,000
Commercialization Agreement And Amended Commercialization Agreement \| Collegium Pharmaceutical Inc \| Royalties and milestones
Collaboration and License Agreements
Total revenues																		155,700,000
Third Party \| Commercialization agreement, net \| Royalties and milestones
Collaboration and License Agreements
Revenues																		29,500,000
Collegium Pharmaceutical Inc \| Commercialization agreement, net
Collaboration and License Agreements
Equal Quarterly Installments of Annual Minimum Royalty Payable						$ 30,800,000		33,800,000	$ 33,800,000	$ 33,800,000
Collegium Pharmaceutical Inc \| Commercialization agreement, net \| NUCYNTA products
Collaboration and License Agreements
Termination penalty				$ 25,000,000.0
Collegium Pharmaceutical Inc \| Amended Commercialization Agreement
Collaboration and License Agreements
Termination penalty					$ 5,000,000
Royalty arrangement, termination notice period					12 months
Collegium Pharmaceutical Inc \| Amended Commercialization Agreement \| Forecast \| Product sales, net
Collaboration and License Agreements
Commercialization agreement, termination, net sales threshold	170,000,000																$ 180,000,000
Collegium Pharmaceutical Inc \| Commercialization Agreement, 14% Royalty On Net Annual Sales \| Forecast \| Third Party
Collaboration and License Agreements
Percentage of royalty on annual net sales																	14.00%				14.00%	14.00%
Minimum \| Forecast \| NUCYNTA products \| Third Party
Collaboration and License Agreements
Revenues																						$ 180,000,000.0
Minimum \| Commercialization Agreement, 14% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					$ 180,000,000
Minimum \| Commercialization Agreement, 58% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					210,000,000
Minimum \| Commercialization Agreement, 20% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					233,000,000
Minimum \| Commercialization Agreement, 25% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold	$ 233,000,000
Minimum \| Collegium Pharmaceutical Inc \| Forecast \| NUCYNTA products \| Third Party
Collaboration and License Agreements
Royalty obligation																						34,000,000.0
Maximum \| Forecast \| Third Party
Collaboration and License Agreements
Royalty obligation																						$ 8,800,000
Maximum \| Commercialization Agreement, 14% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					210,000,000
Maximum \| Commercialization Agreement, 58% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					233,000,000
Royalty arrangement, quarterly payment term	45 days
Maximum \| Commercialization Agreement, 20% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold																					$ 258,000,000
Maximum \| Commercialization Agreement, 25% Royalty On Net Annual Sales \| Forecast \| Collegium Pharmaceutical Inc
Collaboration and License Agreements
Commercialization agreement, net annual sales threshold	$ 258,000,000
Prepaid and other current assets
Collaboration and License Agreements
Contract asset								800,000										800,000
Other long-term assets
Collaboration and License Agreements
Contract asset								$ 1,600,000										$ 1,600,000